Le Lézard
Classified in: Health
Subject: PDT

Avion Pharmaceuticals' new gout prophylaxis product, GLOPERBA®, is the first and only liquid form of colchicine (1,2)


ALPHARETTA, Ga., Feb. 27, 2020 /PRNewswire/ -- Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, announced its gout prophylaxis product, GLOPERBA® (colchicine), is now commercially available in pharmacies across the United States. The FDA approved GLOPERBA 0.6 mg/5 mL on Jan. 30, 2019, but the drug has not been commercially available until now.

Avion Pharmaceuticals

Gout is a debilitating form of arthritis affecting an estimated 8.7 million people in the United States. The disease is caused by elevated levels of uric acid crystals in the joints, which can trigger painful and debilitating inflammation. Gout can become a chronic condition if left untreated.

Physicians have long used colchicine to treat gout, but they are often required to adjust dosing or interrupt treatment to minimize the potential for side effects, especially in patients with liver or kidney disease, which are common comorbidities of gout. Prior to GLOPERBA, colchicine was only available in tablet and capsule forms, which can make dose adjustments difficult for patients. As a liquid oral solution, GLOPERBA allows physicians and patients to easily tailor dosing as needed.

"GLOPERBA brings a new level of flexibility and control to the management of gout with colchicine," said Art Deas, CEO of Avion Pharmaceuticals. "Every gout patient is unique. As a liquid, GLOPERBA gives physicians the power to easily individualize treatment and titrate dosing based on their patients' unique needs."

GLOPERBA (NDC: 75854-801-01) is available at chain, independent, and specialty pharmacies. For more information, please visit GLOPERBA.com.

Please see full Prescribing Information for GLOPERBA.

ML-0103 0220-01

ABOUT AVION PHARMACEUTICALS
Avion Pharmaceuticals, LLC, is a specialty pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the women's heath therapeutic category. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage- development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals, please contact the company at 678-325-5188 or visit www.avionrx.com.

INDICATION
GLOPERBA (colchicine) 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.

GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

IMPORTANT SAFETY INFORMATION FOR GLOPERBA

You are encouraged to report negative side effects of prescription drugs to the FDA. To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References:

1. GLOPERBA [Package Insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2020. 2. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Revised January 17, 2020. Accessed February 5, 2020.


SOURCE Avion Pharmaceuticals, LLC


These press releases may also interest you

at 14:22
The registered nurses of Baystate Franklin Medical Center and Baystate Noble Hospital, represented by the Massachusetts Nurses Association, are calling on Baystate Health to commit to universal N95 masking for frontline nurses and healthcare workers...

at 14:15
In states like Illinois, Colorado and Oregon, hemp & cannabis-related businesses are deemed essential during the COVID-19 Pandemic. There are many reasons for this, the first and foremost reason being the healing benefits of the plant, helping people...

at 14:15
The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in...

at 14:15
A growing number of experts say it is time to rethink official recommendations in the U.S. and other western countries to avoid wearing masks amid the coronavirus pandemic.  Sui Huang, MD, PhD, is a molecular biologist and professor at Institute for...

at 14:10
Overview Sales of orthobiologics for the repair and regeneration of bone totaled nearly $2.4bn in 2018, with sales expected to climb at a CAGR of 3.2% through 2024. Growth in this market will be driven by the aging of the population and the global...

at 14:08
Concert Genetics, a technology company dedicated to advancing precision medicine, today announced the publication of real-world data on utilization and coding variability in medical claims for Next-Generation Sequencing (NGS)-based diagnostic tests....



News published on 27 february 2020 at 09:15 and distributed by: